Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP972216.RAx6hU94QhECnS4ewJ-g3J6dS0WwPeYdkeACLyshp5cXE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP972216.RAx6hU94QhECnS4ewJ-g3J6dS0WwPeYdkeACLyshp5cXE130_assertion type Assertion NP972216.RAx6hU94QhECnS4ewJ-g3J6dS0WwPeYdkeACLyshp5cXE130_head.
- NP972216.RAx6hU94QhECnS4ewJ-g3J6dS0WwPeYdkeACLyshp5cXE130_assertion description "[However, a significant fraction of patients with HER2+ breast cancer treated with these agents eventually relapse or develop progressive disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP972216.RAx6hU94QhECnS4ewJ-g3J6dS0WwPeYdkeACLyshp5cXE130_provenance.
- NP972216.RAx6hU94QhECnS4ewJ-g3J6dS0WwPeYdkeACLyshp5cXE130_assertion evidence source_evidence_literature NP972216.RAx6hU94QhECnS4ewJ-g3J6dS0WwPeYdkeACLyshp5cXE130_provenance.
- NP972216.RAx6hU94QhECnS4ewJ-g3J6dS0WwPeYdkeACLyshp5cXE130_assertion SIO_000772 22471661 NP972216.RAx6hU94QhECnS4ewJ-g3J6dS0WwPeYdkeACLyshp5cXE130_provenance.
- NP972216.RAx6hU94QhECnS4ewJ-g3J6dS0WwPeYdkeACLyshp5cXE130_assertion wasDerivedFrom befree-2016 NP972216.RAx6hU94QhECnS4ewJ-g3J6dS0WwPeYdkeACLyshp5cXE130_provenance.
- NP972216.RAx6hU94QhECnS4ewJ-g3J6dS0WwPeYdkeACLyshp5cXE130_assertion wasGeneratedBy ECO_0000203 NP972216.RAx6hU94QhECnS4ewJ-g3J6dS0WwPeYdkeACLyshp5cXE130_provenance.